Authors

Latest:

Dr Kurz on Social Determinants of Health That Contribute to Disparities in Cancer Care

Renee Kurz, DNP, FNP-BC, AOCNP, discusses social determinants of health that can contribute to disparities in cancer care, highlighting examples seen throughout New Jersey that emphasize the need for further investigation into this landscape.

Dalia Kaakour, MD

Latest:

Dr George on the Efficacy and Safety of Subcutaneous Nivolumab in ccRCC

Saby George, MD, FACP, discusses the efficacy and safety of subcutaneous nivolumab in patients with clear cell renal cell carcinoma, according to findings from the phase 3 CheckMate 67T study.

Rohit Gosain, MD

Latest:

Make Time for Your Own Health

Although graduate medical education at many hospitals includes provisions to ensure that trainees remain physically, emotionally, and mentally healthy, few residents and fellows make use of these resources.

Sara Grisales Jaramillo, LMSW

Latest:

Undocumented Immigrants With Cancer Face Unique Care Challenges

Undocumented immigrants continue to face discriminatory policies, which affect those with cancer on emotional, financial, physical, and social levels.

Jia Luo, MD

Latest:

Dr Luo on Optimal Initial Chemotherapy Regimens in NUT Carcinoma

Jia Luo, MD, discusses a retrospective analysis of initial chemotherapy regimens for the treatment of patients with locally advanced and metastatic NUT carcinoma, which was presented at the 2023 IASLC World Conference on Lung Cancer.

Christina T. Loguidice

Michael Basin, MD

Latest:

Dr Basin on the Methods for Investigating Hsp70 Inhibition in Belzutifan-resistant in RCC

Michael Basin, MD, discusses the design of a preclinical investigation into the pharmacological inhibition of the molecular chaperone Hsp70 and how it relates to belzutifan resistance in clear cell renal cell carcinoma.

Eric Vail, MD

Latest:

Dr. Vail Discusses Emerging Advances in Biomarker Testing in Lung Cancer

Eric Vail, MD, discusses emerging advances in biomarker testing in lung cancer.

Amod Sarnaik, MD

Latest:

TIL Therapy: Lessons Learned and Potential Future Directions in Care

Experts Amod Sarnaik, MD, and Krishna Komanduri, MD, consider lessons learned about TILs and CAR T-cell therapy in hematologic cancers, and how they anticipate TILs fitting into treatment paradigms for solid tumors.

Meghan J. Mooradian, MD

Latest:

Emerging Concepts on the Role of Immunotherapy in NSCLC

Martin Dietrich, MD, PhD, and Meghan J. Mooradian, MD, conclude their discussion by discussing how they address treatment toxicity in NSCLC.

Nishanth Thalambedu, MD

Latest:

Managing TLS and CRS/ICANS: Through the Lens of a First-Year Hematology/Oncology Fellow

Tumor lysis syndrome is an oncologic emergency that every clinician will likely encounter at one time or another, and managing it requires careful consideration of a number of factors.

Priya K Bhatt, APRN

Latest:

Unmet Needs in the Treatment of HR+/HER2- Breast Cancer

Closing their discussion, the panel shares some remaining unmet needs in the treatment and management of patients with HR+/HER- breast cancer.

Jeff Bendix

Latest:

Reducing Burnout Requires an Organizational Response

A new study suggests that reducing physician burnout requires an organizational-level response that focuses on creating of a medical practice culture that value qualities such as teamwork, open communication, and process improvement.

Andrea L. Silber, MD

Latest:

Dr. Silber on the Importance of Improving Clinical Trial Inclusivity in Breast Cancer

Andrea L. Silber, MD, discusses the importance of improving clinical trial inclusivity in breast cancer.

Amer M. Beitinjaneh, MD

Latest:

Dr. Beitinjaneh on the Evaluation of Tabelecleucel in EBV+ Hematologic Malignancies

Amer M. Beitinjaneh, MD, discusses updated results from phase 3 ALLELE trial investigating the use of tabelecleucel in Epstein-Barr Virus–positive post-transplant lymphoproliferative disease following allogeneic hematopoietic stem cell transplant or solid organ transplant after failure of rituximab with or without chemotherapy.

Myriam Chalabi, MD

Latest:

Dr. Chalabi on the Role of MSI Testing in CRC

Myriam Chalabi, MD, discusses the utility of microsatellite instability (MSI) testing in colorectal cancer,

Travis J. Osterman, DO

Latest:

How to Make Clinical Decisions With AI in Oncology

Speculation on the impact of large language models or artificial intelligence in the future of health care is commonplace, causing excitement and concern.

Chih-Yi Liao, MD

Latest:

Dr Liao on the Value of Molecular Testing in Biliary Tract Carcinoma

Chih-Yi Liao, MD, discusses the value of molecular testing in biliary tract carcinoma.

Jonathan Coggins, MHA

Latest:

Physicians Must Become Advocates to Play a Role in Community Oncology’s Future

Although some community oncologists may think they can do little to abate the reimbursement reform forces that are affecting their practices, there are actions they can, and should, take to influence the success of their value-based care journey that may not be part of the fundamentals of their current practice.

Patricia Pautier, MD

Latest:

Dr. Pautier on Results of the LMS-02 Trial in Uterine and Soft Tissue Sarcomas

Patricia Pautier, MD, discusses the results of the phase 2 LMS-02 trial with doxorubicin and trabectedin in uterine and soft tissue leiomyosarcoma.